Obesity
-
Social Media Is Touting New Weight Loss Drugs. Are Regulators Watching?
Competition to claim a market that could be worth $100 billion a year for drugmakers alone has triggered a wave of advertising that has provoked the concern of regulators and doctors worldwide.
-
MedCity Pivot: Blue Shield of California CEO Says Value of HealthTech Has Been Mixed So Far
Paul Markovich believes in the value of health tech in managing both chronic diseases and in general health and wellness. In this episode, he talks about the company’s Wellvolution platform and the digital tools that are offered there to members, now even to those on Medicaid.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Structure Therapeutics’ IPO Raises $161M for Pills to Rival Blockbuster Biologics
Despite challenging financial market conditions, clinical-stage Structure Therapeutics was able to upsize its IPO. Much of the new cash will support its lead program, an oral small molecule that could weigh in on the diabetes and obesity indications currently dominated by blockbuster injectable medicines.
-
The White House Wants To Prevent Obesity, but We Also Need To Treat It
Prevention is critical, and the ideas put forth in the White House’s proposal will likely help many Americans—particularly children—avoid weight gain as well as the downstream effects of obesity and its comorbidities. But more than 42% of U.S. adults already have obesity, and they need help now.
-
Amgen Weighs In to Chase Rival Obesity Drugs From Novo Nordisk and Eli Lilly
An Amgen drug led to weight loss that was sustained, clinical data that support advancing the molecule to a Phase 2 test expected to start in early 2023. While AMG 133 trails rival products from Novo Nordisk and Eli Lilly, Amgen hopes to offer patients a dosing edge.
-
MedCity Influencers, BioPharma
What tirzepatide means for the fight against obesity
For individuals who have tried and failed to find success with diet and exercise alone, we now have one more weapon and one more reason for hope.
-
MedCity Influencers, Opinion, BioPharma
Lowering insulin prices isn’t the (only) answer to helping patients with diabetes
It is time to shift the conversation, incentives, and policy solutions to help people improve their health and get off of medications—not just make them cheaper.
-
Why obesity intervention needs to be a bigger part of chronic disease care
Obese patients are more at risk for diabetes, cardiovascular disease, certain cancers and mortality than patients who maintain a healthy weight, and obese patient who develop these chronic conditions usually have more complications. That is why providers and payers must integrate more weight loss strategies in chronic condition care, panelists argued at a Tuesday panel hosted by the Chamber of Commerce.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Hospitals, MedCity Influencers, Consumer / Employer, Physicians
Obesity is a disease—and it’s treatable
Obesity is a disease, and America’s healthcare providers and hospital systems must be part of changing how we treat it. That means many of us in the health ecosystem must reexamine how we view patients with excess weight.
-
Versanis Bio unveils $70M and a Novartis drug ready for Phase 2 test in obesity
Novartis was unsuccessful developing bimagrumab as a treatment for a rare muscle disorder, but additional tests showed encouraging results in fat reduction. Startup Versanis Bio licensed rights to the antibody and plans to use its Series A financing for clinical trials testing the drug in obese patients.
-
America’s obesity epidemic requires action, not posturing
Pinterest’s move to outright ban all ads referring to weight loss — regardless of quality of information — is woefully misguided, writes a former Pinterest executive.
-
Eisai to pull obesity drug after post-marketing study reveals increased cancer risk
The voluntary withdrawal was in response to an FDA request. Eisai said its interpretation of the data differed from the agency’s, but the drug’s original developer had called off pursuit of European approval when regulators there pointed to potential tumor risk from long-term use.
-
Gilead NASH drug dead in the water as second Phase III trial fails
An analyst wrote that with selonsertib’s failures in fourth- and now third-stage fibrosis, the drug will have no place in NASH treatment. Gilead has entered partnerships focused on other compounds for the fatty liver disease.
-
Artificial Intelligence, BioPharma
Gilead, Insitro in $250M machine learning partnership to develop NASH drugs
The deal comes days after Gilead partnered on clinical development in NASH with Denmark’s Novo Nordisk, and two months after the high-profile failure of a Phase III study in the disease.